Sertraline
Product Images NDC 64205-965

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Sertraline (NDC 64205-965). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Readymeds, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Photo 2 (Photo 2)

Packaging label for Sertraline 50 mg tablets by ReadyMeds, showing a 30-count package. Includes the NDC number 64205-965-30, expiration date of 11/2016, and lot number G310689.*

FDA Label Image

Photo (Photo)

Sertraline 50 mg label from ReadyMeds, displaying the proprietary name, strength, quantity (#90), NDC 64205-965-90, expiration date 11/2016, and lot number G310689.*

FDA Label Image

Chemical Structure (Sertraline HCl Tablets New Ndc 1)

Chemical structure of Sertraline hydrochloride, showing the molecular framework with chlorine-substituted aromatic rings and a hydrochloride group attached to the amine nitrogen.*

FDA Label Image

Table 2 Most Common Treatment-emergent Adverse Events: Incidence In Placebo-controlled Clinical Trials (Sertraline HCl Tablets New Ndc 2)

Data table titled 'Most Common Treatment-Emergent Adverse Events: Incidence in Placebo-Controlled Clinical Trials' showing percentages of patients reporting various adverse events. It compares Sertraline and placebo groups across several conditions including Major Depressive Disorder, OCD, Panic Disorder, and PTSD by body system and specific adverse events such as autonomic nervous system disorders, central and peripheral nervous system disorders, gastrointestinal disorders, and psychiatric disorders.*

FDA Label Image

Table 2 (Sertraline HCl Tablets New Ndc 3)

Table presenting adverse event incidence rates by body system in patients treated with Sertraline versus placebo for PMDD (daily and luteal phase dosing) and Social Anxiety Disorder, comparing percentages of various side effects such as somnolence, tremor, fatigue, nausea, insomnia, and more across treatment groups.*

FDA Label Image

Table 3 (Sertraline HCl Tablets New Ndc 4)

Table showing the incidence of treatment-emergent adverse events in placebo-controlled clinical trials for Sertraline versus placebo. Data covers various body systems including autonomic nervous system, central and peripheral nervous system, skin, gastrointestinal, general, psychiatric disorders, and special senses. Percentages reflect patients reporting events for each category.*

FDA Label Image

Table 4 (Sertraline HCl Tablets New Ndc 5)

A data table titled 'Most Common Adverse Events Associated with Discontinuation in Placebo-Controlled Clinical Trials.' It lists adverse events such as abdominal pain, agitation, anxiety, diarrhea, dizziness, etc., across various conditions and groups including Major Depressive Disorder, OCD, Panic Disorder, PTSD, PMDD daily dosing, PMDD luteal phase dosing, and Social Anxiety Disorder, showing percentage occurrence for each event.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.